Asuragen said this week that it has received a notice of allowance from the US Patent and Trademark Office for claims related to the use of microRNA-205 as a diagnostic for lung cancer.
"Human miR-205 has been identified as being highly expressed in lung cancer when compared with its expression in normal lung tissue, and, as a result, is an excellent marker for use as a diagnostic for lung cancer," the company said.